13 results about "Microangiopathy" patented technology

The present application relates to novel substituted heterocyclic carboxamides, to processes for their preparation, to their use alone or in combinations for the treatment and / or prevention of diseases and to their use for producing medicaments for the treatment and / or prevention of diseases, in particular for the treatment and / or prevention of breathing difficulties including sleep-induced breathing difficulties such as central and obstructive sleep apnoea, snoring (primary and obstructive snoring), dysphagia, peripheral and cardiac vascular disorders including diabetic microangiopathies and disorders of the peripheral and central nervous system including neurodegenerative and neuroinflammatory disorders.

The present invention relates to in vitro sialylated human factor H protein or biologically active sialylated fragments or biologically active sialylated variants thereof for use in treating paroxysmal nocturnal hemoglobinuria, for treating thromboinflammation, for treating pathological platelet aggregate formation for treating microangiopathy, and / or for treating Long COVID. Combination with a C5 inhibitor, e.g. eculizumab, is also envisaged.

The present application relates to novel substituted heterocyclic carboxamides, methods of their preparation, their use alone or in combination for the treatment and / or prevention of diseases and their use for the manufacture of a medicament for the treatment and / or prevention of diseases, in particular for the treatment and / or prevention of respiratory distress, including sleep-induced respiratory distress, such as central and obstructive sleep apnea, snoring (primary and obstructive snoring); dysphagia; peripheral and cardiovascular disorders, including diabetic microangiopathy; and peripheral and central nervous system disorders, including neurodegenerative and neuroinflammatory disorders.

The present application relates to novel substituted heterocyclic carboxamides, to a method for the production thereof, to the use thereof alone or in combination for the treatment and / or prophylaxis of diseases and to the use thereof for producing medicaments for the treatment and / or prophylaxis of diseases, in particular for the treatment and / or prophylaxis of dyspnea, including sleep-induced dyspnea, including sleep-induced dyspnea, including sleep-induced dyspnea. Such as central and obstructive sleep apnea, snoring (primary and obstructive snoring); dysphagia; peripheral and cardiovascular conditions, including diabetic microangiopathy; and peripheral and central nervous system disorders, including neurodegenerative and neuroinflammatory disorders.

The application belongs to the technical field of pharmaceutical preparations, and particularly relates to a pharmaceutical composition for treating diabetic microangiopathy and a preparation method thereof, the pharmaceutical composition comprising the following raw materials in parts by weight: active drug 5-10 parts, shell copolymer 20 parts, PLGA 35-50 parts, emulsifier 1.5 parts and freeze-drying protective agent 4 parts. The shell copolymer prepared and synthesized from PCL, PEG and a targeting peptide has functions such as drug loading, self-assembly, responsiveness and targeting, the responsiveness of which depends on a disulfide bond connecting the PCL and the PEG, the disulfide bond is broken in an abnormal blood flow environment of a vascular lesion, various drugs in the nanoparticle core are released, and the drug delivery efficiency and the treatment effect are greatly improved.

The present invention covers the use of chymase inhibitors in general and more in particular substituted bicyclically substituted uracils of general formula (I) as described and defined herein, and 3-methylbenzo-[b]thiophene)-2-sulfonamido derivatives of general formula (II) for manufacturing pharmaceutical compositions for the treatment or prophylaxis of stroke, pulmonary embolism, deep or superficial vein thrombosis, thrombotic microangiopathy, thrombotic microangiopathy in hypercoagulable states after infection, inflammation, transplantation, disseminated intravascular coagulation, vaccine-induced immune thrombotic thrombocytopenia, vascular access site thrombosis or occlusion.

The application relates to the technical field of traditional Chinese medicines, and discloses application of a traditional Chinese medicine composition in preparation of a medicine for preventing or treating diabetic microangiopathy, wherein the traditional Chinese medicine composition can improve blood perfusion and blood oxygen content of the foot skin of a diseased rat, reduce whole blood viscosity, has a certain protective effect on eyeball retina injury of a diabetic vasculopathy rat, inhibits infiltration of inflammatory cells in kidney tissue of a diabetic microangiopathy rat, improves glomerular basement membrane morphology, improves edema of proximal tubular epithelial cells, has a certain protective effect on foot skin injury of a diabetic microangiopathy rat, and reduces ET-1 level and Cys-C level in serum.

The invention discloses a biomarker for auxiliary diagnosis of SLE (systemic lupus erythematosus) and application of the biomarker, and belongs to the technical field of biology. The invention discloses one of an anti-NPM1 antibody, an anti-RPLP2 antibody and an anti-MX1 antibody or a combination of any two or three of the anti-NPM1 antibody, the anti-RPLP2 antibody and the anti-MX1 antibody, which can be used as a biomarker for auxiliary diagnosis of SLE. And the kit can be used for auxiliary monitoring of SLE disease activity and auxiliary diagnosis of SLE (combined anti-phospholipid antibody) with clinical phenotypes of arterial thrombosis, microangiopathy, heart valve enuresis and thrombocytopenia, and has good diagnosis efficiency.

The invention relates to ADAMTS13 protein variants comprising residues 1 to 685 of ADAMTS13 and wherein one or more N-linked glycosylation sites are added as compared to wild-type ADAMTS13 and / or one or more existing N-linked glycosylation sites are shifted as compared to wild-type ADAMTS13. The invention further relates to compositions comprising such ADAMTS13 variants, methods for their preparation and uses thereof, in particular as an antithrombotic agent, and in the treatment of thrombotic disease, thrombotic microangiopathy, thrombotic thrombocytopeniaurpura (TTP), hemolytic-uremic syndrome (HUS), ischemic stroke, systemic thrombosis, COVID19, antiphospholipid syndrome, pre-eclampsia / HELLP syndrome, sepsis and sickle cell disease.

In one aspect, the invention provides methods and compositions for inhibiting MASP-3-dependent complement activation in a subject suffering from or at risk for developing, a disease or disorder selected from the group consisting of paroxysmal nocturnal hemoglobinuria, age-related macular degeneration, arthritis, disseminated intravascular coagulation, thrombotic microangiopathy, asthma, dense deposit disease, pauci-immune necrotizing crescentic glomerulonephritis, traumatic brain injury, aspiration pneumonia, endophthalmitis, neuromyelitis optica and Behcet's disease by administering to the subject a composition comprising an amount of a MASP-3 inhibitory agent in an amount effective to inhibit MASP-3-dependent complement activation. In some embodiments, the subject is administered a MASP-2 inhibitory agent and a MASP-1 inhibitory agent, a MASP-2 inhibitory agent and a MASP-3 inhibitory agent administered, a MASP-3 inhibitory agent and a MASP-1 inhibitory agent, or a MASP-1 inhibitory agent, a MASP-2 inhibitory agent and a MASP-3 inhibitory agent.

The application discloses a kind of IV collagen targeted calcium dobesilate enteric microsphere capsules and preparation method thereof, belong to the technical field of pharmaceutical preparation.The capsule takes calcium dobesilate as main drug, adopts chitosan-sodium alginate ion crosslinking microsphere as carrier, is modified by RGD base sequence small peptide of specific binding IV collagen, and is wrapped Eudragit L100 enteric coating layer, realizes the dual action of active targeting and passive targeting.The application solves the problems of weak targeting, poor gastric acid stability and low bioavailability of existing calcium dobesilate preparation, and the enrichment concentration of drug in retinal and renal microvascular lesion site is increased by more than 4 times, while the stability and dissolution uniformity of the preparation are significantly improved.The preparation process is simple, suitable for industrial mass production, and can be used for preparing drugs for treating diabetic retinopathy and diabetic nephropathy.

In one aspect, the invention provides methods and compositions for inhibiting MASP-3-dependent complement activation in a subject suffering from or at risk for developing, a disease or disorder selected from the group consisting of paroxysmal nocturnal hemoglobinuria, age-related macular degeneration, arthritis, disseminated intravascular coagulation, thrombotic microangiopathy, asthma, dense deposit disease, pauci-immune necrotizing crescentic glomerulonephritis, traumatic brain injury, aspiration pneumonia, endophthalmitis, neuromyelitis optica and Behcet's disease by administering to the subject a composition comprising an amount of a MASP-3 inhibitory agent in an amount effective to inhibit MASP-3-dependent complement activation. In some embodiments, the subject is administered a MASP-2 inhibitory agent and a MASP-1 inhibitory agent, a MASP-2 inhibitory agent and a MASP-3 inhibitory agent administered, a MASP-3 inhibitory agent and a MASP-1 inhibitory agent, or a MASP-1 inhibitory agent, a MASP-2 inhibitory agent and a MASP-3 inhibitory agent.

The present invention relates to in vitro sialylated human factor H protein or biologically active sialylated fragments or biologically active sialylated variants thereof for use in treating paroxysmal nocturnal hemoglobinuria, for treating thromboinflammation, for treating pathological platelet aggregate formation for treating microangiopathy, and / or for treating Long COVID. Combination with a C5 inhibitor, e.g. eculizumab, is also envisaged.